Sex Differences in the Association of Leisure Time Physical Activity and Incident Peripheral Artery Disease
Abstract Body (Do not enter title and authors here): Background: The benefit of leisure time physical activity (LTPA) in preventing peripheral artery disease (PAD) is well established. However, no prior studies have examined how longitudinal changes in LTPA during mid-life influence the risk of future PAD in men and women.
Methods: We included participants from the Atherosclerosis Risk in Communities (ARIC) study who attended visit 3 and were free of PAD [ankle brachial index (ABI) >0.90] with available ABI during follow-up (measured ~5, 18, and 25 years after visit 3). LTPA was assessed using the modified Baecke questionnaire and defined as ideal, intermediate, or poor by the American Heart Association. Change in LTPA from visit 1 (1987-1989) to 3 (1993-1995) was subcategorized as 1) persistently poor, 2) decreased, 3) increased, or 4) persistently active. The primary outcome of time-to-incident PAD after visit 3 (ABI ≤ 0.90), was assessed using Cox models adjusted for relevant covariates.
Results: A total of 8,421 participants were included (mean age 59 ± 5.5 years, 56% women, 20% Black). From visit 1 to 3, 1,609 participants had persistently poor LTPA, 1,860 decreased their activity, 2,015 increased their activity, and 2,937 remained persistently active. During a median follow-up of 17.7 years, 853 ARIC participants developed PAD (471 women and 382 men). An increasing or persistently active level of LTPA was associated with lower risk of incident PAD (HR 0.74 (0.60, 0.89) p=0.003 and HR 0.71 (0.58, 0.85) p<0.001 respectively) compared to persistently poor LTPA. There was no difference between those in the decreasing LTPA category and those with persistently poor LTPA (HR 0.88 (0.72, 1.09) p=0.24). There were no interactions with race, age, or body mass index; however, there was significant effect modification by sex (p-int 0.01). Men who increased activity or were persistently active had lower risk of developing PAD as compared to those with persistently poor LTPA (Table). There was no association between changes in LTPA and incident PAD in women.
Conclusions: Maintaining or increasing LTPA over six years was associated with decreased risk of incident PAD in men but not in women. Further research is needed to clarify sex differences in these associations.
Pabon, Maria
( Brigham and Women's Hospital
, Boston
, Massachusetts
, United States
)
Foa', Alberto
( Brigham and Women's Hospital
, Boston
, Massachusetts
, United States
)
Claggett, Brian
( Brigham and Women's Hospital
, Boston
, Massachusetts
, United States
)
Evenson, Kelly
( UNC Department of Epidemiology
, Chapel Hill
, North Carolina
, United States
)
Matsushita, Kuni
( JOHNS HOPKINS UNIVERSITY
, Baltimore
, Maryland
, United States
)
Solomon, Scott
( Brigham and Women's Hospital
, Boston
, Massachusetts
, United States
)
Hegde, Sheila
( Brigham and Women's Hospital
, Boston
, Massachusetts
, United States
)
Author Disclosures:
Maria Pabon:DO NOT have relevant financial relationships
| Alberto Foa':DO NOT have relevant financial relationships
| Brian Claggett:DO have relevant financial relationships
;
Consultant:Cardior:Active (exists now)
; Consultant:Eli Lilly:Active (exists now)
; Consultant:CVRx:Past (completed)
; Consultant:Intellia:Active (exists now)
; Consultant:Cytokinetics:Past (completed)
; Consultant:Cardurion:Active (exists now)
| Kelly Evenson:DO NOT have relevant financial relationships
| Kuni Matsushita:DO have relevant financial relationships
;
Consultant:RhythmX AI:Active (exists now)
; Research Funding (PI or named investigator):Resolve to Save Lives:Active (exists now)
; Other (please indicate in the box next to the company name):Fukuda Denshi:Past (completed)
| Scott Solomon:DO have relevant financial relationships
;
Research Funding (PI or named investigator):Alexion, Alnylam, Applied Therapeutics, AstraZeneca, Bellerophon, Bayer, BMS, Boston Scientific, Cytokinetics, Edgewise, Eidos/BridgeBio, Gossamer, GSK, Ionis, Lilly,NIH/NHLBI, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Tenaya, Theracos, US2.AI:Active (exists now)
; Consultant:Abbott, Action, Akros, Alexion, Alnylam, Amgen, Arena, AstraZeneca, Bayer, BMS, Cardior, Cardurion, Corvia, Cytokinetics, GSK, Intellia, Lilly, Novartis, Roche, Theracos, Quantum Genomics, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros, Valo:Active (exists now)
| Sheila Hegde:No Answer